Prognostic scores in primary biliary cholangitis patients with advanced disease

Juan Feng; Jia-Min Xu; Hai-Yan Fu; Nan Xie; Wei-Min Bao; Ying-Mei Tang

doi:10.4240/wjgs.v15.i8.1774

Prognostic scores in primary biliary cholangitis patients with advanced disease

World J Gastrointest Surg. 2023 Aug 27;15(8):1774-1783. doi: 10.4240/wjgs.v15.i8.1774.

Authors

Juan Feng¹, Jia-Min Xu¹, Hai-Yan Fu¹, Nan Xie¹, Wei-Min Bao², Ying-Mei Tang³

Affiliations

¹ Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China.
² Department of General Surgery, Yunnan Provincial First People's Hospital, Kunming 650032, Yunnan Province, China.
³ Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, Yunnan Province, China. tangyingmei_med@kmmu.edu.cn.

Abstract

Background: Due to the chronic progressive disease characteristics of primary biliary cholangitis (PBC), patients with advanced PBC should not be ignored. Most prognostic score studies have focused on early stage PBC.

Aim: To compare the prognostic value of various risk scores in advanced PBC to help PBC patients obtain more monitoring and assessment.

Methods: This study considered patients diagnosed with PBC during hospitalization between 2015 and 2021. The clinical stage was primarily middle and late, and patients usually took ursodeoxycholic acid (UDCA) after diagnosis. The discriminatory performance of the scores was assessed with concordance statistics at baseline and after 1 year of UDCA treatment. Telephone follow-up was conducted to analyze the course and disease-associated outcomes. The follow-up deadline was December 31, 2021. We compared the risk score indexes between those patients who reached a composite end point of death or liver transplantation (LT) and those who remained alive at the deadline. The combined performance of prognostic scores in estimating the risk of death or LT after 1 year of UDCA treatment was assessed using Cox regression analyses. Predictive accuracy was evaluated by comparing predicted and actual survival through Kaplan-Meier analyses.

Results: We included 397 patients who were first diagnosed with PBC during hospitalization and received UDCA treatment; most disease stages were advanced. After an average of 6.4 ± 1.4 years of follow-up, 82 patients had died, and 4 patients had undergone LT. After receiving UDCA treatment for 1 year, the score with the best discrimination performance was the Mayo, with a concordance statistic of 0.740 (95% confidence interval: 0.690-0.791). The albumin-bilirubin, GLOBE, and Mayo scores tended to overestimate transplant-free survival. Comparing 7 years of calibration results showed that the Mayo score was the best model.

Conclusion: The Mayo, GLOBE, UK-PBC, and ALBI scores demonstrated comparable discriminating performance for advanced stage PBC. The Mayo score showed optimal discriminatory performance and excellent predictive accuracy.

Keywords: Cholangitis; Liver transplantation; Mayo score; Primary biliary cholangitis; Prognostic value.